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doi:10.1016/j.ejvs.2011.10.011The invited commentary of Dr. Reekers1 discussing our original
article on venous angioplasty in chronic cerebrospinal venous
insufﬁciency in multiple sclerosis patients (CCSVI-MS)2 may be
more suited to an opinion-based section of the journal rather
than a section requiring academic standards to be met when
writing commentary about a peer-reviewed article.
Although it would be appropriate to start our reply discussing
some key scientiﬁc issues raised in the commentary, Dr.
Weinstock-Guttman and Dr. Zivadinov would like to take this
opportunity to provide more detailed information on the ‘new
chapter’.
We met Dr. Zamboni in 2008, when he presented his prelimi-
nary research at Grand Rounds in Buffalo, at our MS centre. We
were intrigued by the new theory Dr. Zamboni presented, and
decided that it would be important to prove or disprove some of
his proposed hypotheses while taking advantage of our Buffalo
research capabilities. Since then, more than 25 peer-reviewed arti-
cles have been generated either as part of our collaboration or as
a result of our individual efforts, some of them published in the
most prestigious world journals.1 Additional articles are in press
or ready for submission and several more are expected from other
groups around the world to provide the ultimate scientiﬁc truth.
This is why we became doctors in the ﬁrst place – to advance
knowledge in whatever direction it takes us.
Given our experience in collaborating with Dr. Zamboni, we are
more than qualiﬁed to declare that he is exceedingly trying to ﬁnd
the truth, as all of us are, for the beneﬁt of MS patients and
those affected with CCSVI. Therefore, we strongly disagree with
Dr. Reekers’ insinuation about well-planned ‘PR’ strategies by
Dr. Zamboni.
Furthermore, based on the research so far, it is yet to be deter-
mined whether the presence of CCSVI may be associated with
speciﬁc consequences, such as clinical symptoms or signs in MS
patients or even in non-MS individuals. Finding the answer to
this hypothesis will ultimately determine whether we will call
CCSVI a syndrome, a disease or something else. For now, we areiety for Vascular Surgery. Publishejust theorising! Our ﬁrst study to ascertain risk factors for CCSVI
in healthy individuals is now in press.4
Dr. Reekers says in his commentary: “Cerebral hypoperfusion is
a recognized phenomenon in MS and is due to decreased arterial
inﬂow, while iron deposits have no relationship with MS. End of
story, however.” We have been studying the magnetic resonance
imaging (MRI) features of MS for the past 15 years and could write
a multi-page reply to such erroneous assertions, which are not sup-
ported in the literature. For example, iron deposition involvement
in MS is present from the earliest stages, and may not be a late
epiphenomenon,5 as it was considered in the past. We need to
keep our minds open as future research will reveal whether the
well-known facts were really well-known after all.
As we presented in our article,2 the purpose of the study we
designed was not to test clinical and MRI efﬁcacy of the endo-
vascular therapy but to provide preliminary safety results and
experience, based on which further placebo-controlled phase I,
II and III trials could be better designed.3 Double-blinded, rand-
omised, placebo-controlled trials are already under way in our
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